Transforming Heart Failure Diagnostics
CHF-AI is a breakthrough AI-powered rapid diagnostic platform designed to revolutionize heart failure detection. Delivering NT-ProBNP results in just 15 minutes, CHF-AI combines advanced lateral flow technology with AI-driven imaging analysis, enabling real-time, high-precision diagnostics in ERs, urgent care, telemedicine, and home care settings.
Heart failure affects 64M+ people globally, with rising hospitalizations driving over $100B in annual healthcare costs.
Point-of-care diagnostics is projected to exceed $75B by 2028, growing at 10-12% annually.
Telemedicine & home care adoption are fueling demand for decentralized, AI-powered solutions like CHF-AI.
Why CHF-AI?
- ✔ 15-Minute NT-ProBNP Results – Enables faster clinical decisions, reducing ER congestion and hospital stays.
✔ AI-Powered Precision – Delivers quantitative biomarker accuracy, improving early heart failure detection.
✔ Seamless Integration – Plug-and-play with telemedicine, home monitoring, and hospital systems.
✔ Scalable Global Model – Addressing both developed & emerging markets with a cost-effective, high-impact solution.
Projected Growth & Expansion
Year 1-2
FDA approval & US market entry, targeting ERs, urgent care, and telehealth networks.
Year 3-5
Global expansion into Europe, Asia, and the Middle East, forging key partnerships in healthcare & insurance.
Year 5+
Projected $700M+ revenue, positioning CHF-AI as the gold standard for AI-driven heart failure diagnostics.
The Future of Heart Failure Management
With unmatched speed, precision, and scalability, CHF-AI is reshaping cardiovascular care. Investors have a unique opportunity to back a high-growth, AI-powered diagnostic leader in an expanding multi-billion-dollar market.